Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCNT1 | O60563 | 6/20 | 0.54 |
| ▸ | FLT3 | P36888 | 2/20 | 0.52 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.44 |
| ▸ | CDK9 | P50750 | 2/20 | 0.43 |
| ▸ | EIF2AK2 | P19525 | 1/20 | 0.43 |
| ▸ | BACE1 | P56817 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.40 |
| ▸ | DYRK1B | Q9Y463 | 2/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.40 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.40 |
| ▸ | MTOR | P42345 | 1/20 | 0.40 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10323703 | 0.92 | CCNT1 (0.49) | CCNT1FLT3LMNACXCR4CDK9 | |
| SCHEMBL10322579 | 0.91 | FLT3 (0.61) | CCNT1FLT3LMNACXCR4EIF2AK2 | |
| SCHEMBL10323677 | 0.91 | LMNA (0.52) | CCNT1FLT3LMNACXCR4CDK9 | |
| SCHEMBL10322853 | 0.87 | FLT3 (0.50) | CCNT1FLT3LMNACXCR4CDK9 | |
| SCHEMBL10322363 | 0.85 | CCNT1 (0.45) | CCNT1FLT3LMNACXCR4CDK9 | |
| SCHEMBL10322415 | 0.83 | FLT3 (0.51) | CCNT1FLT3CDK9EIF2AK2BACE1 | |
| SCHEMBL10354002 | 0.83 | FLT3 (0.51) | CCNT1FLT3CDK9EIF2AK2BACE1 | |
| SCHEMBL10322654 | 0.82 | HRH3 (0.42) | CCNT1FLT3LMNACDK9 | |
| SCHEMBL10323194 | 0.82 | FLT3 (0.50) | CCNT1FLT3CDK9EIF2AK2BACE1 | |
| SCHEMBL10323187 | 0.81 | EIF2AK2 (0.53) | FLT3LMNACXCR4EIF2AK2BACE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8362023-B2 | Pyrazolo pyrimidines | HOFFMANN-LA ROCHE INC. (US) | 2013-01-29 | — | — | US | claimed |
| US-20120184508-A1 | PYRAZOLO PYRIMIDINES | BIODURO (BEIJING) COMPANY LTD. (CN) | 2012-07-19 | — | — | US | claimed |
| US-8362023-B2 | Pyrazolo pyrimidines | HOFFMANN-LA ROCHE INC. (US) | 2013-01-29 | — | — | US | disclosed |
| US-8362023-B2 | Pyrazolo pyrimidines | HOFFMANN-LA ROCHE INC. (US) | 2013-01-29 | — | — | US | disclosed |
| WO-2012098068-A1 | PYRAZOLO PYRIMIDINES AS DYRK1A AND DYRK1B INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2012-07-26 | — | — | WO | disclosed |
| WO-2012098068-A1 | PYRAZOLO PYRIMIDINES AS DYRK1A AND DYRK1B INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2012-07-26 | — | — | WO | disclosed |
| US-20120184508-A1 | PYRAZOLO PYRIMIDINES | BIODURO (BEIJING) COMPANY LTD. (CN) | 2012-07-19 | — | — | US | disclosed |
| US-20120184508-A1 | PYRAZOLO PYRIMIDINES | BIODURO (BEIJING) COMPANY LTD. (CN) | 2012-07-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120184508-A1 | PYRAZOLO PYRIMIDINES | TYMS, TYMP, TP53 | CCNT1 182/4885FLT3 1618/4885LMNA 1710/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.